Krystal Biotech to Participate in Cowen’s 42nd Annual Health Care Conference
Krystal Biotech (NASDAQ: KRYS) announced that CEO Krish S. Krishnan will participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference held virtually from March 7-9, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Krystal Biotech (NASDAQ: KRYS) announced that CEO Krish S. Krishnan will participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference held virtually from March 7-9, 2022. The chat is scheduled for March 7, 2022, from 2:50 to 3:20 p.m. EST. Investors can access the webcast link here. Krystal Biotech specializes in redosable gene therapy, aiming to develop treatments for serious diseases, including rare skin and lung conditions. For further details, visit the official website.
Details
News Market Reaction – KRYS
The recorded move for KRYS in the trading session of this news was +5.26%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PITTSBURGH, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference, which is taking place virtually March 7-9, 2022.
Details are as follows:
| Fireside Chat Date: | Monday, March 7, 2022 |
| Fireside Chat Time: | 2:50-3:20 p.m. EST |
| Webcast link: | https://wsw.com/webcast/cowen108/krys/2056797 |
A webcast of the presentation will be available for 90 days and can be found on the Krystal Biotech website at http://ir.krystalbio.com/events-and-presentations/events.
About Krystal Biotech
Krystal Biotech, Inc. (NASDAQ:KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to potentially bring life-changing treatment options to patients with serious diseases, including rare diseases in skin, lung and other areas. For more information, please visit http://www.krystalbio.com and follow @KrystalBiotech on LinkedIn and Twitter.
CONTACTS:
Investors:
Whitney Ijem
Krystal Biotech
wijem@krystalbio.com
Media:
Tiffany Hamilton
Krystal Biotech
thamilton@krystalbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.